(Q34756218)

4 August 2017

1 reference

title

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance (English)

1 reference

4 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

George V Papatheodoridis

series ordinal

1

1 reference

4 August 2017

Evangelini Dimou

series ordinal

2

1 reference

4 August 2017

Vasilios Papadimitropoulos

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

The American Journal of Gastroenterology

4 August 2017

published in

1 reference

4 August 2017

volume

97

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

1618-1628

1 reference

The treatment of chronic viral hepatitis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Diagnosis and management of pre-core mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

Melatonin prevents pigment gallstone formation induced by bile duct ligation in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05819.X

10.1111/J.1572-0241.2002.05819.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference